PRRT Survival Data for Neuroendocrine Tumors

Alpha-Emitter PRRT

79% PFS

Estimated progression-free survival rate at 20 months in patients receiving 177Lu-DOTATATE plus octreotide LAR, compared to 62% in the control group, in the phase III NETTER-1 trial.

Strosberg et al., New England Journal of Medicine, 2017

Strosberg et al., New England Journal of Medicine, 2017

View as image

Peptide receptor radionuclide therapy (PRRT) delivers targeted radiation to neuroendocrine tumors by attaching a radioactive isotope to a somatostatin analog peptide that binds somatostatin receptors overexpressed on tumor cells. The approach uses the same peptide for both diagnosis (imaging with 68Ga-DOTATATE PET) and treatment (therapy with 177Lu-DOTATATE), a theranostic strategy that ensures only patients whose tumors express the target receptor receive treatment.

The alpha-emitter PRRT pillar article covers the next generation of radioactive peptides. This article focuses on what the clinical data actually shows: survival outcomes, response rates, quality of life, toxicity, and what factors predict who benefits most from PRRT.

The NETTER-1 trial: the pivotal evidence

The NETTER-1 trial, published in the New England Journal of Medicine in 2017, was the phase III randomized controlled trial that led to FDA approval of 177Lu-DOTATATE (Lutathera) in 2018. It enrolled 229 patients with well-differentiated, progressive, somatostatin receptor-positive midgut neuroendocrine tumors.

Patients were randomized to receive either four cycles of 177Lu-DOTATATE (7.4 GBq per cycle) plus long-acting octreotide (30 mg) or high-dose octreotide LAR (60 mg) alone. The results established PRRT as a standard treatment option.

Virgolini et al. (2026) summarized the complete NETTER-1 dataset, including long-term follow-up: the estimated progression-free survival rate at 20 months was 65.2% in the 177Lu-DOTATATE group versus 10.8% in the control group. The objective response rate was 18% versus 3%. Quality of life assessments showed a median time to deterioration in global health status of 28.8 months with PRRT versus 6.1 months with octreotide alone, and physical functioning deterioration at 25.2 versus 11.5 months.^[1]

The final overall survival analysis was complicated by crossover: 36% of patients in the control group subsequently received 177Lu-DOTATATE. The hazard ratio for overall survival was 0.84 (95% CI: 0.60-1.17), which did not reach statistical significance, though the crossover design biased the analysis against detecting a true survival difference.

Real-world outcomes

Clinical trial populations are selected: patients must meet strict inclusion criteria. Real-world data from routine clinical practice helps determine whether NETTER-1 results hold outside controlled trial conditions.

United States

Hentzen et al. (2023) reported outcomes from a U.S. center treating patients with 177Lu-DOTATATE in routine practice. Median overall survival from first PRRT cycle was 37.2 months, and median progression-free survival was 24.3 months. The disease control rate (complete response + partial response + stable disease) was 86%. These results are consistent with NETTER-1 outcomes and suggest that the benefits of PRRT are reproducible in standard clinical settings.^[2]

Xu et al. (2024) analyzed PRRT outcomes from two U.S. medical centers, focusing on renal and hematological toxicity alongside survival. Median overall survival was 34.8 months. The study found that baseline renal function and hematological parameters predicted both toxicity risk and survival duration, suggesting these measures could guide patient selection.^[3]

Europe

Pretot et al. (2023) published outcome analysis from a Swiss center treating patients with metastatic gastroenteropancreatic NETs. Their analysis confirmed the NETTER-1 efficacy signal and identified tumor grade, Ki-67 index, and baseline tumor burden as prognostic factors for response duration. Patients with lower Ki-67 (less aggressive tumors) derived longer benefit from PRRT.^[4]

Asia

Shin et al. (2024) reported the first Korean real-world data on Lu-177 DOTATATE PRRT. Among 41 patients with unresectable or metastatic NETs, the disease control rate was 82.9% and median progression-free survival was 28.8 months. Objective partial response was observed in 14.6% and stable disease in 68.3%. These results demonstrate that PRRT efficacy is consistent across different ethnic populations and healthcare systems.^[5]

Organ-specific responses

Mamulashvili et al. (2025) used sequential 68Ga-DOTATOC PET/CT to evaluate organ-specific responses to PRRT in patients with metastatic small intestine NETs. Liver metastases showed the best response to treatment, while mesenteric masses responded less favorably. This suggests that PRRT efficacy varies by metastatic site, which has implications for treatment planning and response monitoring.^[6]

Factors that predict response

Not all neuroendocrine tumor patients benefit equally from PRRT. Several factors influence outcomes.

Somatostatin receptor expression. PRRT only works if the tumor expresses somatostatin receptors at sufficient density to concentrate the radiopeptide. Pre-treatment 68Ga-DOTATATE PET imaging is mandatory: tumors must show uptake exceeding liver background to be candidates. Hofland et al. (2022) reviewed the evidence that higher baseline tumor uptake on somatostatin receptor PET correlates with better PRRT response.^[7]

Tumor grade. Well-differentiated NETs (WHO grade 1-2, Ki-67 <20%) respond better than poorly differentiated neuroendocrine carcinomas. The NETTER-1 trial enrolled only well-differentiated tumors. Pretot et al. (2023) confirmed that Ki-67 index is a significant predictor of progression-free survival after PRRT.^[4]

Tumor burden. Patients with extensive hepatic metastases have higher renal and hematological toxicity risk and may derive less durable benefit, though they can still respond.

Prior treatment lines. Most PRRT data comes from patients who have progressed on somatostatin analogs. Earlier use of PRRT (before extensive prior therapy) may produce better outcomes, though this hypothesis is being tested in the NETTER-2 trial.

Toxicity and safety

Hematological toxicity

Mohindroo et al. (2026) reviewed PRRT toxicity management comprehensively. Grade 3-4 hematological toxicity (severe cytopenias) occurs in approximately 10% of patients. The most concerning long-term hematological complication is therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), which occurs in approximately 2-3% of treated patients, typically 1-5 years after PRRT. This risk must be weighed against the survival benefit, particularly in patients with limited treatment options.^[8]

Renal toxicity

The kidneys are a dose-limiting organ because the radiopeptide is renally excreted and reabsorbed by proximal tubules. Amino acid co-infusion (lysine and arginine) during PRRT reduces renal uptake and is standard practice. Xu et al. (2024) found that baseline renal function (GFR) predicted post-treatment renal decline, and patients with pre-existing renal impairment required closer monitoring.^[3]

Grade 3-4 renal toxicity is uncommon (<1% in NETTER-1), but gradual loss of renal function over years post-treatment occurs and requires long-term monitoring.

Nausea and other acute effects

Acute nausea during and after PRRT infusion occurs in approximately 25-30% of patients. Fatigue and abdominal discomfort are also common but typically mild and self-limiting.

PRRT beyond gastroenteropancreatic NETs

While NETTER-1 established PRRT for midgut NETs, the therapy is being explored in other somatostatin receptor-positive tumors.

Santo et al. (2025) reviewed PRRT applications beyond gastroenteropancreatic NETs: meningiomas, lung neuroendocrine tumors, pheochromocytomas, paragangliomas, and other rare somatostatin receptor-expressing tumors all show evidence of PRRT response. The key requirement is somatostatin receptor expression, not the tumor's tissue of origin. If 68Ga-DOTATATE PET shows sufficient uptake, the tumor is a potential PRRT candidate regardless of histological classification.^[9]

Alqahtani et al. (2025) conducted a systematic review and meta-analysis of non-surgical treatments for pancreatic NETs specifically. PRRT showed efficacy in pancreatic NETs with favorable somatostatin receptor expression, though the evidence base is smaller than for midgut NETs because NETTER-1 did not include pancreatic primary tumors.^[10]

Evolving treatment strategies

Combination approaches

Merola and Grana (2023) reviewed innovations in PRRT including combination strategies: PRRT with chemotherapy (CAPTEM regimen), PRRT with targeted therapies (everolimus), and PRRT with external beam radiation. Early data suggests combinations may improve outcomes in higher-grade tumors that respond partially to PRRT alone, though randomized trial data for most combinations is pending.^[11]

Harris and Zhernosekov (2022) discussed next-generation PRRT approaches including second-generation high-specific-activity Lu-177, which delivers more radiation per milligram of peptide. Improved radionuclide production quality may enhance tumor dosimetry and treatment outcomes.^[12]

Alpha-emitter PRRT

Leupe et al. (2025) reported clinical experience with targeted alpha-emitter PRRT using 225Ac-DOTATATE or 212Pb-DOTATATE. Alpha particles deposit more energy over shorter distances than the beta particles emitted by Lu-177, potentially producing higher tumor cell kill with less damage to surrounding tissue. Early clinical data shows responses in patients who have progressed after standard Lu-177 PRRT, suggesting alpha-emitter therapy may extend the PRRT treatment paradigm for patients who exhaust standard options.^[13]

More on this approach is covered in the pillar article on alpha-emitter PRRT.

Retreatment

For patients who initially responded to PRRT and later progressed, retreatment with additional cycles of 177Lu-DOTATATE is being studied. U.S. center data suggests retreatment can achieve renewed disease control in a substantial proportion of patients, with response rates and progression-free survival that, while generally shorter than first-line PRRT, still represent clinically meaningful benefit. The evidence remains limited to retrospective series. Cumulative toxicity, particularly bone marrow reserve and renal function, must be carefully assessed before retreatment, as the margin for safe dosing narrows with each treatment line.

Somatostatin receptor antagonists

Santo et al. (2024) reviewed the emerging approach of using somatostatin receptor antagonist peptides rather than agonists for PRRT. Antagonist-based radiopeptides bind more receptor sites on tumor cells (because they do not trigger receptor internalization), potentially delivering higher radiation doses to tumors. Preclinical and early clinical data is promising but has not yet reached phase III trials.^[14]

For background on how Lutathera (177Lu-DOTATATE) works at the molecular level, and how PRRT is explained as a therapeutic approach, see the dedicated cluster articles. The octreotide for neuroendocrine tumors article covers the somatostatin analog therapy that typically precedes PRRT.

The Bottom Line

PRRT with 177Lu-DOTATATE produces clinically meaningful improvements in progression-free survival, objective response, and quality of life for patients with somatostatin receptor-positive neuroendocrine tumors. The NETTER-1 trial established the evidence base, and real-world data from the U.S., Europe, and Asia confirms these results translate to routine clinical practice. Response varies by somatostatin receptor expression, tumor grade, and metastatic site. Hematological toxicity and a small risk of therapy-related myeloid neoplasms require long-term monitoring. The field is moving toward alpha-emitter isotopes, antagonist-based radiopeptides, and combination strategies that may extend PRRT's reach and efficacy.

Frequently Asked Questions

What is the survival rate for PRRT in neuroendocrine tumors?

In the NETTER-1 phase III trial, 177Lu-DOTATATE plus octreotide produced an estimated 20-month progression-free survival rate of 65.2% versus 10.8% for high-dose octreotide alone. Real-world U.S. data shows median overall survival of approximately 35-37 months from first PRRT cycle (Hentzen et al., 2023; Xu et al., 2024). Korean real-world data reported median progression-free survival of 28.8 months (Shin et al., 2024). Individual outcomes depend on tumor grade, receptor expression, and tumor burden.

How effective is Lutathera for neuroendocrine tumors?

Lutathera (177Lu-DOTATATE) produces objective tumor shrinkage in approximately 18% of patients and disease stabilization in an additional 65-70%, for a disease control rate exceeding 80%. The quality of life benefit is substantial: median time to deterioration in global health was 28.8 months with Lutathera versus 6.1 months with octreotide alone in NETTER-1 (Virgolini et al., 2026). It is most effective in well-differentiated tumors with high somatostatin receptor expression confirmed by 68Ga-DOTATATE PET.

What are the side effects of PRRT?

The most common acute side effects are nausea (25-30%), fatigue, and abdominal discomfort. Grade 3-4 hematological toxicity (severe drops in blood counts) occurs in approximately 10% of patients. The most serious long-term risk is therapy-related myelodysplastic syndrome or acute myeloid leukemia, occurring in 2-3% of patients within 1-5 years after treatment (Mohindroo et al., 2026). Renal toxicity is minimized by amino acid co-infusion but requires long-term monitoring. Kidney function gradually declines in some patients.

Who is eligible for PRRT treatment?

PRRT candidates must have somatostatin receptor-positive tumors confirmed by 68Ga-DOTATATE PET/CT imaging, with tumor uptake exceeding liver background. Patients must have well-differentiated neuroendocrine tumors (typically WHO grade 1-2) that have progressed on somatostatin analog therapy. Adequate baseline kidney function and blood counts are required. Hofland et al. (2022) reviewed the imaging criteria that determine eligibility: higher baseline tumor uptake correlates with better treatment response.

Can PRRT be used for tumors other than GI neuroendocrine tumors?

Yes. Santo et al. (2025) reviewed PRRT in meningiomas, lung neuroendocrine tumors, pheochromocytomas, paragangliomas, and other somatostatin receptor-expressing tumors. The key requirement is somatostatin receptor expression, not tumor origin. If 68Ga-DOTATATE PET shows adequate uptake, the tumor may respond to PRRT regardless of primary site. The evidence base for non-GEP-NET indications is smaller and based primarily on retrospective series rather than randomized trials.

What happens after PRRT stops working?

Options after PRRT progression include retreatment with additional 177Lu-DOTATATE cycles (retrospective data supports renewed disease control), alpha-emitter PRRT using 225Ac-DOTATATE or 212Pb-DOTATATE (Leupe et al., 2025 reported responses in Lu-177-refractory patients), combination with chemotherapy or targeted agents, and clinical trial enrollment. The emerging antagonist-based radiopeptides may also offer activity in patients who have exhausted standard PRRT (Santo et al., 2024).